PLXND1 and non-small cell lung carcinoma: Specifically, circ-PLXND1 silencing inhibits NSCLC progression via miR1287–5p upregulation and human Epidermal Growth Factor Receptor 3 (ERBB3) suppression (97) (Figure 4B).